Le Lézard
Classified in: Science and technology
Subject: SLS

Securitas AB to publish the Interim report January-March 2022


STOCKHOLM, April 27, 2022 /PRNewswire/ -- Securitas AB will publish the Interim report for January-March 2022 on Wednesday, May 4, 2022, at approximately 1.00 p.m. (CET). 

App. 1.00 p.m. (CET) Report release
The report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released.

2.00 p.m. (CET) Presentation slides available 
For presentation slides, follow the link www.securitas.com/presentations 

2.30 p.m. (CET) Telephone conference and audio cast
Analysts and media are invited to participate in a telephone conference at 2.30 p.m. (CET) where Securitas President and CEO Magnus Ahlqvist and CFO Andreas Lindback will present the report and answer questions. The telephone conference will also be audio casted live via Securitas' website. To participate in the telephone conference, please dial in five minutes prior to the start of the conference call:

United States:  + 1 631 913 1422
Sweden:  + 46 8 566 426 51
United Kingdom: + 44 333 3000 804
Please use the following pin code for the telephone conference: 621 490 78#

To follow the audio cast of the telephone conference via the web, please follow the link www.securitas.com/webcasts.

A recorded version of the audio cast will be available on the same web page after the telephone conference. We value your privacy and want to be transparent with you on the way that we collect and use your personal data when you participate in the telephone conference. Please follow this link to read our privacy policy for telephone conferences/audio casts in relation to publication of interim reports: www.securitas.com/privacy-policy-audiocasts.

Further information:

Investors: Micaela Sjökvist, Vice President, Investor Relations; +46 76 116 7443, [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/securitas/r/securitas-ab-to-publish-the-interim-report-january-march-2022,c3554154

The following files are available for download:

https://mb.cision.com/Main/1062/3554154/1569846.pdf

Invitation Q1 2022

SOURCE Securitas


These press releases may also interest you

at 21:00
Full Sail University Kicks Off 14th Annual Hall of Fame Week with "Hall of Game" Esports Event
Full Sail University's Annual Hall of Fame week kicked off with "Hall of Game." This esports event welcomed students and alumni to compete in popular titles including Call of Duty, Rocket League, and Super Smash Bros. Through Full Sail's partnership...

at 21:00
TIER IV to launch robotaxi business in Tokyo, November 2024: Starting with limited operational domains
TIER IV, a pioneer in developing open-source software for autonomous driving (AD) systems, is set to launch a unique robotaxi service in November 2024. Initially targeting areas and times that conventional taxi operators struggle to serve, the...

at 20:14
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 20:00
SUNRATE joins Mastercard's Priceless Planet Coalition
SUNRATE, an intelligent global payment and treasury management platform today announced it has joined Mastercard Priceless Planet Coalition in support of fighting climate change through funding the restoration of 100 million trees. This announcement...

at 20:00
E&R Engineering Corp. Unveils Cutting-Edge Solutions at Semicon SEA 2024 in Kuala Lumpur
The advanced laser and plasma solution provider from Taiwan, E&R Engineering Corp., is confirmed to attend the feast in Semiconductor industry, Semicon SEA 2024, held in Kuala Lumpur, Malaysia. With the 30-year dedication in the semiconductor...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

More news about Science and technology...


News published on and distributed by: